Clinical Trials
11
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302)
- Conditions
- Axillary Hyperhidrosis
- Interventions
- Drug: Sofpironium Bromide, 15%Drug: Vehicle
- First Posted Date
- 2019-05-14
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Botanix Pharmaceuticals
- Target Recruit Count
- 351
- Registration Number
- NCT03948646
- Locations
- 🇺🇸
Cahaba Dermatology Skin & Health Center, Birmingham, Alabama, United States
🇺🇸Advanced Research Associates, Glendale, Arizona, United States
🇺🇸Arkansas Research Trials, North Little Rock, Arkansas, United States
Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301)
- Conditions
- Axillary Hyperhidrosis
- Interventions
- Drug: Sofpironium Bromide Gel, 15%Drug: Vehicle
- First Posted Date
- 2019-02-11
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Botanix Pharmaceuticals
- Target Recruit Count
- 350
- Registration Number
- NCT03836287
- Locations
- 🇺🇸
Total Skin and Beauty Dermatology Center, P.C., Birmingham, Alabama, United States
🇺🇸Investigate MD, LLC, Scottsdale, Arizona, United States
🇺🇸Northwest Arkansas Clinical Trials Center, Rogers, Arkansas, United States
Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis
- First Posted Date
- 2019-01-31
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- Botanix Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT03824405
- Locations
- 🇺🇸
Applied Research Center of Arkansas Inc., Little Rock, Arkansas, United States
🇺🇸T. Joseph Raoff MD Inc. / Encino Research Center, Encino, California, United States
🇺🇸Center for Dermatology Clinical Research, Fremont, California, United States
A Safety Study of BBI-4000 Gel in Pediatric Patients With Axillary Hyperhidrosis
- Conditions
- Primary Axillary Hyperhidrosis
- Interventions
- Drug: Sofpironium Bromide Gel, 15%
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2023-03-14
- Lead Sponsor
- Botanix Pharmaceuticals
- Target Recruit Count
- 21
- Registration Number
- NCT03785587
- Locations
- 🇺🇸
Northwest Arkansas Clinical Trials Center, Rogers, Arkansas, United States
A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis
- Conditions
- Primary Axillary Hyperhidrosis
- Interventions
- Drug: Sofpironium Bromide Gel, 5%Drug: Sofpironium Bromide Gel, 15%
- First Posted Date
- 2018-08-13
- Last Posted Date
- 2023-05-19
- Lead Sponsor
- Botanix Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT03627468
- Locations
- 🇺🇸
Coastal Clinical Research, Inc., Mobile, Alabama, United States
🇺🇸Northwest Arkansas Clinical Trials Center, Rogers, Arkansas, United States
🇺🇸Center for Clinical and Cosmetic Research, Aventura, Florida, United States
- Prev
- 1
- 2
- 3
- Next